Search hospitals > Texas > San Antonio
NEXT Oncology
Claim this profileSan Antonio, Texas 78229
Global Leader in Solid Tumors
Global Leader in Cancer
Conducts research for Lung Cancer
Conducts research for Metastases
Conducts research for Colorectal Cancer
162 reported clinical trials
12 medical researchers
Summary
NEXT Oncology is a medical facility located in San Antonio, Texas. This center is recognized for care of Solid Tumors, Cancer, Lung Cancer, Metastases, Colorectal Cancer and other specialties. NEXT Oncology is involved with conducting 162 clinical trials across 130 conditions. There are 12 research doctors associated with this hospital, such as Anthony Tolcher, M.D, David Sommerhalder, MD, Sharon T Wilks, MD, FACP, and Raghad Karim, MD.Area of expertise
1Solid Tumors
Global LeaderStage IV
Stage III
KRAS positive
2Cancer
Global LeaderStage IV
Stage III
KRAS positive
Top PIs
Anthony Tolcher, M.DNEXT Oncology4 years of reported clinical research
Expert in Solid Tumors
Expert in Cancer
38 reported clinical trials
52 drugs studied
David Sommerhalder, MDNEXT Oncology2 years of reported clinical research
Expert in Solid Tumors
Expert in Cancer
27 reported clinical trials
35 drugs studied
Sharon T Wilks, MD, FACPTexas Oncology - San Antonio Medical Center4 years of reported clinical research
Studies Breast Cancer
Studies Endometrial Cancer
5 reported clinical trials
13 drugs studied
Raghad Karim, MDNEXT Oncology5 years of reported clinical research
Studies Solid Tumors
Studies Gastric Cancer
3 reported clinical trials
3 drugs studied
Clinical Trials running at NEXT Oncology
Solid Tumors
Cancer
Lung Cancer
Breast Cancer
Colorectal Cancer
Metastases
Prostate Cancer
Pancreatic Cancer
Ovarian Cancer
Non-Small Cell Lung Cancer
DCC-3116
for Solid Tumors
This trial tests a new drug, DCC-3116, alone and with other drugs, in patients with advanced cancers that have specific genetic mutations. The drug works by blocking a pathway that helps cancer cells grow.
Recruiting3 awards Phase 1 & 230 criteria
HH2853
for Non-Hodgkin's Lymphoma
This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II. HH2853 will be administered orally on a continuous BID schedule on a continuous 28-day treatment cycle.
Recruiting1 award Phase 1 & 2
APR-1051
for Cancer
The purpose of this study is to assess the safety and effectiveness of APR-1051 through the performance of a Phase 1, open-label, safety, PK, and preliminary efficacy study of oral APR-1051 in patients with advanced solid tumors.
Recruiting1 award Phase 14 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at NEXT Oncology?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.